Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

Provided is an objective and convenient index for judging full recovery from atopic dermatitis and severity thereof. The present invention provides a diagnosis assisting method for determining a treatment policy for an atopic dermatitis subject under the treatment, said method comprising: measuring the expression value of SCCA-1 in skin horny cells of the subject; i) when the SCCA-1 expression value is not statistically significantly higher than the level of those who do not suffer from atopic dermatitis, then determining that the continuation of the treatment for the disease becomes unnecessary thanks to the treatment; and, in the case where the continuation of the treatment is determined as still necessary, ii) ranking the severity of atopic dermatitis of the subject using the SCCA-1 expression value as an index and determining an adequate treatment method for atopic dermatitis to be given to the subject depending on the rank.

Embodiments include obtaining a stroma liquid biopsy from a patient and detecting a pattern of dysregulation amongst the biomarkers in the stroma liquid biopsy that can be monitored to help screen, diagnose or treat the patient for cancer. The biomarkers in the stroma liquid biopsy are involved in interconnected pathways such as the coagulation pathway, acute-phase inflammation pathway, and complement pathway. Particular embodiments involve assaying for levels of biomarkers, such as neutrophil elastase, as well as subpopulations of other biomarkers, such as subpopulations of SERPIN proteins. The levels of biomarkers and/or the ratios of levels of biomarker subpopulations can be informative for predicting the cancer disease state in the patient, thereby enabling more personalized or tailored medical intervention for the patient.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

The invention provides assay methods of detecting plasma protease C1 inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

Methods and computer methods used to assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over a 1 to 5 year period are provided. The methods employ at least two biomarkers selected from MMP12, angiopoietin-2, complement C7, cardiac troponin I, angiopoietin-related protein 4, CCL18/PARC, alpha-1-antichymotrypsin complex, GDF11 and alpha-2-antiplasmin, or GDF11 in combination with FSTL3. The methods are particularly useful in predicting CV events in patients who suffer from coronary heart disease (CHD).

Provided herein are methods of determining a subject's risk of developing a cardiac arrhythmia, methods of treating a subject having or at risk of developing a cardiac arrhythmia, methods of selecting a treatment for a subject having or at risk of developing a cardiac arrhythmia, methods of selecting a subject for administration of a treatment for reducing risk of developing a cardiac arrhythmia, methods of determining the efficacy of a treatment in a subject having or at risk of developing a cardiac arrhythmia, and methods of monitoring a subject having or at increased risk of developing a cardiac arrhythmia based on a level of one or more of glucocorticoid (GC), corticosteroid-binding globulin (CBG), and neutrophil elastase (NE). Also provided are kits that include two or more of an antibody that binds specifically to GC, an antibody that binds specifically to GBC, and an antibody that binds specifically to NE.

A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor.

Coagulation and fibrinolysis assays and related compositions, systems, methods, and kits are provided. In some embodiments, a coagulation and fibrinolysis assay may utilize one or more biological molecules. For instance, the assay may comprise combining a blood or blood-derived patient sample with the biological molecule(s) and measuring one or more properties of the sample associated with coagulation and/or fibrinolysis. The biological molecules may serve to shorten the assay duration and/or enhance the sensitivity of the assay relative to certain conventional assays. In certain embodiments, the biological molecules may allow pathological coagulation and/or fibrinolysis phenotypes to be elucidated. The coagulation and fibrinolysis assays described herein may be used for a wide variety of clinical and/or laboratory applications, including the diagnosis of certain coagulation and/or fibrinolysis disorders, such as trauma-induced coagulopathy and hyperfibrinolysis.

The present invention relates to an ex-vivo model of inflamed skin, an in-vitro method for obtaining the same and uses thereof for screening anti-inflammatory compounds.